logo BDSP

Base documentaire


  1. A trial of the synthetic malaria vaccine SPf66 in Tanzania : rationale and design.

    Article - En anglais

    The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials.

    SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia.

    This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.

    Mots-clés Pascal : Plasmodium falciparum, Sporozoa, Protozoa, Vaccin, Produit synthétique, Essai clinique phase III, Homme, Tanzanie, Afrique, Innocuité, Immunogénicité, Paludisme, Protozoose, Infection

    Mots-clés Pascal anglais : Plasmodium falciparum, Sporozoa, Protozoa, Vaccine, Synthetic product, Phase III trial, Human, Tanzania, Africa, Harmlessness, Immunogenicity, Malaria, Protozoal disease, Infection

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0206067

    Code Inist : 002B05E02B4. Création : 199406.